Uptake of Biogen’s Tecfidera and Increased Availability of Merck KGaA’s Mavenclad Fueling Significant Increase in Oral Disease-Modifying Therapy Share of Multiple Sclerosis Patients in Europe to the Detriment of Teva’s Copaxone
Lack of access to Roche’s Ocrevus for primary progressive multiple sclerosis has stymied UK prescriber base growth and adoption over the past six months as much of Ocrevus’ early adoption in other EU countries came from first-line use among primary progressive multiple sclerosis patients due to the high unmet need and the agent’s first-to-market indication, […]
More Rheumatologists are Using Pfizer’s Xeljanz in Psoriatic Arthritis Patients, Outpacing the Impressive Growth Displayed by Eli Lilly’s Taltz in the Previous Quarter
Download Report Overview EXTON, Pa., Oct. 8, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 100 US rheumatologists reveals that Xeljanz’s user base has increased by a greater margin than the user base for Taltz for the treatment of psoriatic arthritis (PsA) over the last three […]
Analysis of Over 1,000 Atopic Dermatitis Patients Highlights Moderate-to-Severe Patient Candidacy for Biologics and Small Molecules and Real-World Treatment Patterns for Patients Treated With Sanofi/Regeneron’s Dupixent
Candidacy analysis for pipeline agents reveals that JAK inhibitors, such as Pfizer’s PF-0496582, AbbVie’s upadacitinib and Incyte’s topical ruxolitinib have the most potential upside if approved Download Report Overview EXTON, Pa., September 27, 2018 (Newswire.com) – To better understand what real-world moderate and severe atopic dermatitis patients look like in terms of disease burden, physician […]
Ocrevus Climbing as First-line DMT for RRMS Among Neurologists Surveyed in Spherix Report
From: Multiple Sclerosis News Today By: Alice Melao
Ocrevus Predicted to Be a Billion-dollar Blockbuster
From: Multiple Sclerosis News Today By: Ed Tobias The research firm Spherix Global Insights, which analyzes trends in the pharmaceutical industry, predicts that Ocrevus is “poised to blow past the $1B mark in the coming year. …” (read more).
Biosimilars in Nephrology: Pfizer’s Retacrit Gets FDA Clearance and Prepares to Challenge Amgen’s Anemia Franchise Head On
The latest quarterly anemia report from Spherix Global Insights indicates a receptive audience for biosimilar erythropoietin stimulating agents (ESAs), but also a pre-dialysis market looking for ESA-alternatives to anemia management. Download Report Overview EXTON, Pa., May 31, 2018 /PRNewswire/ — Following the receipt of two Complete Response Letters from the FDA related to manufacturing issues, […]
TNF Cycling in Psoriatic Arthritis Declines for the Second Year in a Row as Newly Approved Agents Such as Pfizer’s Xeljanz and Eli Lilly’s Taltz Claim Their Share of the Switching Population
According to Spherix Global Insights, data from over 1,000 psoriatic arthritis patients who recently switched therapies reveals that clinical factors, such as joint and skin efficacy, often drive the decision to switch, while non-clinical factors often influence the choice of the new brand. Download Report Overview EXTON, Pa., May 30, 2018 /PRNewswire/ — With four […]
Pfizer’s Xeljanz Barrels into Psoriatic Arthritis, Leaving Lilly’s Recently Launched Taltz in its Wake, According to a Recently Published Study from Spherix Global Insights
Janssen’s Simponi Aria and BMS’ Orencia seem to be settling into their respective niches, but neither brand is anticipated to bring much disruption to the PsA market Download Report Overview EXTON, Pa., April 9, 2018 /PRNewswire/ — The most recent quarterly results of a study conducted by Spherix Global Insights with 101 US rheumatologists reveals […]
US Dermatologists Delighted with Sanofi/Regeneron’s Dupixent, but Increased Familiarity and Experience with Pfizer’s Eucrisa May be Breeding Contempt
According to a recent study conducted by Spherix Global Insights, US dermatologists (n=104) report significantly higher satisfaction with Dupixent than with any of the other approved agents for the treatment of atopic dermatitis, while Eucrisa garners the lowest satisfaction ratings. Download Report Overview EXTON, Pa., Nov. 30, 2017 /PRNewswire/ — The most recent release of […]
Dermatologists’ Six Month Projections Reveal Janssen’s Tremfya Closing in on the IL-17 Inhibitors, Novartis’ Cosentyx and Eli Lilly’s Taltz, in Psoriasis
According to Spherix Global Insights’ latest quarterly release of RealTime Dynamix™: Psoriasis, adoption of Tremfya as a psoriasis treatment is largely comparable to that of Taltz’s at a similar post-launch timeframe. Download Report Overview EXTON, Pa., Nov. 29, 2017 /PRNewswire/ — At approximately four months post-launch, over one-third of surveyed dermatologists (n=101) have prescribed Tremfya, […]
